Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under £2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses.
The London-based drug discovery and development company reported a pretax loss of £1.1 million in the six months that ended June 30, narrowed from £1.8 million a year before.
ImmuPharma booked £69,959 in revenue, compared to none a year before. More importantly, research and development expenses were reduced to £828,767 from £1.0 million and administrative expenses to £412,277 from £555,600. The company also swung to net finance income of £161,355 from net finance expense of £160,301.
ImmuPharma said it raised £1.4 million from subscriptions to 67.5 million new shares at 2 pence each. The subscriptions were by finance provider and current 8.0% shareholder Lanstead Capital Investors LP, together with an institutional investor who wasn’t named.
ImmuPharma shares were down 9.8% at 2.16p each in London early Thursday afternoon.
The company also launched a retail offer via the Winterflood Retail Access Platform to raise up to £500,000 from the sale of 25.0 million new shares at the same 2p price.
‘We continue to make positive progressive steps for ImmuPharma,’ said Chair & Chief Executive Officer Tim McCarthy. ‘As a board, we remain focused on bringing our two key late stage P140 clinical assets in Lupus and [chronic idiopathic demyelinating polyneuropathy] through their final clinical trials and to the market.’
Copyright 2023 Alliance News Ltd. All Rights Reserved.